Allogene Therapeutics Inc (ALLO)

NASDAQ HEALTHCARE
$2.17 -3.56% RSI 49 Neutral Add Alert

Moving Averages

SMA 200
$1.65
Price above

Company Profile

Allogene Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and markets genetically engineered allogeneic T-cell therapies for the treatment of cancer. The company is headquartered in South San Francisco, California.

Sector
HEALTHCARE
Industry
BIOTECHNOLOGY
Market Cap
$793.56M
P/E Ratio
None
EPS
$-0.87
Beta
0.46
Dividend Yield
0.00%
52-Week High
$4.46
52-Week Low
$0.941

Similar stocks in BIOTECHNOLOGY

BNTX
BioNTech SE
RSI 44.0
VRTX
Vertex Pharmaceuticals Inc
RSI 50.0
CRSP
CRISPR Therapeutics AG
RSI 55.0
MRNA
Moderna Inc
RSI 41.0
VKTX
Viking Therapeutics Inc
RSI 48.0
SRPT
Sarepta Therapeutics Inc
RSI 42.0
EDIT
Editas Medicine Inc
RSI 59.0
IOVA
Iovance Biotherapeutics Inc
RSI 54.0
NVAX
Novavax Inc
RSI 60.0
DNA
Ginkgo Bioworks Holdings Inc - Class A
RSI 58.0

Data last updated: May 14, 2026 at 3:53 AM EDT

Track ALLO for free

Get e-mail RSI alerts when Allogene Therapeutics Inc enters oversold or overbought territory. Free forever.

Add Alert